Literature DB >> 14534933

Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease.

Mark S Baron, W Brian Dalton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14534933     DOI: 10.1002/mds.10551

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  5 in total

1.  A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

Authors:  Kimberly E Vanover; Adrienne J Betz; Suzanne M Weber; Francesco Bibbiani; Aiste Kielaite; David M Weiner; Robert E Davis; Thomas N Chase; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

2.  Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.

Authors:  Giuseppe Meco; Paola Stirpe; Fabrizio Edito; Carlo Purcaro; Marcella Valente; Silvia Bernardi; Nicola Vanacore
Journal:  J Neural Transm (Vienna)       Date:  2009-05-12       Impact factor: 3.575

Review 3.  The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox
Journal:  Exp Brain Res       Date:  2013-06-28       Impact factor: 1.972

4.  Treatment of Levodopa-induced Dyskinesia.

Authors:  Jayaraman Rao
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

5.  A Case of Fahr's Disease Presenting as Chorea Successfully Treated by the Use of Quetiapine.

Authors:  Syoichiro Kono; Yasuhiro Manabe; Tomotaka Tanaka; Daiki Fujii; Yasuko Sakai; Hisashi Narai; Nobuhiko Omori; Koji Abe
Journal:  Clin Med Case Rep       Date:  2009-10-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.